Telmisartan

證據等級: L5

預測適應症: 10 個

Telmisartan: From Hypertension to Intracerebral Hemorrhage (Secondary Prevention)

One-Sentence Summary

Telmisartan is an angiotensin II receptor blocker (ARB) with an established, well-known role in hypertension management. Within this evidence pack, Intracerebral Hemorrhage (secondary stroke prevention) emerged as the strongest of ten TxGNN-predicted candidates, supported by 3 registered clinical trials (including a completed Phase 3 RCT enrolling 1,671 patients) and 8 relevant publications. However, the drug is not currently registered for marketing in South Africa, and key local safety data are missing.

Note on candidate selection: this pack screened 10 TxGNN-predicted indications for telmisartan. Most (Prinzmetal angina, brain stem infarction, ABri amyloidosis, pulmonary hypertension subtypes, Braddock syndrome) had model scores only, with zero supporting trials or drug-specific literature (Evidence Level L5, recommendation “Hold”). Intracerebral hemorrhage had by far the strongest supporting evidence and is presented as the lead candidate below; cerebral artery occlusion (L2) is the next-best alternative and is referenced where relevant.

Quick Overview

Item	Content
Original Indication	Hypertension (established ARB indication; not sourced from this pack — see note below)
Predicted New Indication	Intracerebral Hemorrhage (secondary prevention)
TxGNN Prediction Score	99.93%
Evidence Level	L1
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Note: This evidence pack contains no original_indications or SAHPRA licence records for telmisartan, and original_moa is flagged as a data gap. “Hypertension” above reflects the drug’s globally established use, not pack-sourced data.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data (formal original_moa field) is not available in this pack. Based on the mechanistic rationale accompanying the evidence, telmisartan is an angiotensin II type 1 (AT1) receptor blocker — it inhibits the renin-angiotensin-aldosterone system (RAAS), lowering blood pressure and blood pressure variability, which are key drivers of small-vessel wall stress in the brain.

Intracerebral hemorrhage (ICH) recurrence is strongly linked to poorly controlled hypertension and vascular wall fragility. RAAS blockade is mechanistically plausible for reducing recurrence risk by lowering BP variability and vessel wall stress. This is reinforced by preclinical work showing AT1 blockade reduces apoptosis, inflammation, and oxidative stress in ICH and subarachnoid hemorrhage models, and by telmisartan’s distinct lipid solubility/PPAR-γ agonism (“metabo-sartan” profile), which has been associated with additional neuroprotective effects in animal stroke models.

Most directly, telmisartan is the active BP-lowering component of the TRIDENT trial’s “Triple Pill” strategy, a Phase 3 RCT specifically designed to test intensive BP lowering for recurrent ICH prevention — making this one of the few candidates in the pack with a purpose-built clinical trial rather than only mechanistic inference.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02699645	Phase 3	Completed	1,671	TRIDENT main trial: fixed low-dose “Triple Pill” BP-lowering strategy vs. standard care, in patients with prior ICH, for time to recurrent stroke. Direct, purpose-built RCT for this indication; outcome results not included in this pack and require separate verification.
NCT03783754	N/A	Terminated	4	TRIDENT MRI sub-study; terminated with only 4 patients enrolled — statistically uninformative.
NCT03785067	Phase 3	Terminated	1	TRIDENT cognitive sub-study; terminated with 1 patient enrolled — no usable evidence.

Secondary candidate — cerebral artery occlusion (L2) evidence includes NCT01075698 (Phase 4, Completed, n=1,228, general cardiovascular risk population, not occlusion-specific).

No SANCTR or PACTR-registered trials were found for these indications in this pack.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34994269	2022	Review	Int J Stroke	Rationale and design of the TRIDENT trial for recurrent ICH prevention.
24636673	2014	Cohort	Int J Stroke	PRoFESS trial sub-analysis: race-ethnic differences in ischemic vs. hemorrhagic stroke recurrence rates.
19148963	2009	Correspondence	N Engl J Med	Commentary on telmisartan for prevention of cardiovascular events.
17538008	2007	Preclinical/Animal	J Pharmacol Exp Ther	AT1 receptor blockade with telmisartan reduces apoptosis, inflammation, and oxidative stress in a normotensive rat ICH model.
27078703	2016	Preclinical/Animal	Neurological Research	Telmisartan reduces oxidative stress and cerebral vasospasm after subarachnoid hemorrhage in animal models.
40045320	2025	Preclinical/Animal	J Neuroinflammation	Development of cerebral microhemorrhages in an angiotensin II-induced hypertensive mouse model.
15834293	2005	Preclinical/Animal	J Hypertension	Telmisartan vs. ramipril: comparative effects on cerebrovascular structure in spontaneously hypertensive rats.
22957022	2012	Preclinical/Animal	PLoS One	Differential effects of telmisartan vs. candesartan on pial arteriole diameter in hypertensive rats.

South Africa Market Information

Telmisartan currently has no SAHPRA registration records in this evidence pack (market status: not marketed, 0 licenses). No product name, dosage form, or approved indication text is available for South Africa.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Key warnings, contraindications, and drug interaction data are flagged as blocking data gaps in this pack — see Conclusion below.)

Conclusion and Next Steps

Decision: Hold

Rationale: Intracerebral hemorrhage is the best-supported candidate in this pack (Evidence Level L1, one purpose-built completed Phase 3 RCT with 1,671 patients), but two blocking factors prevent moving forward: telmisartan is not currently registered for marketing in South Africa, and local safety/prescribing data (TFDA/SAHPRA warnings and contraindications) are an identified blocking data gap (DG001).

To proceed, the following is needed:

TRIDENT trial (NCT02699645) outcome/efficacy results — this pack only confirms the trial exists and completed, not its findings
SAHPRA-approved Professional Information (PI) for telmisartan — warnings, contraindications, and drug interaction data (blocking gap DG001)
Formal mechanism-of-action documentation from DrugBank or manufacturer (gap DG002)
Clarification of the South African market access/registration pathway given current “not marketed” status
If pursued further, comparative evaluation against the secondary candidate (cerebral artery occlusion, L2) identified in this same screening pass
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.